Final Results of ERASME-4: A Randomized Trial of First-Line Docetaxel plus either Capecitabine or Epirubicin for Metastatic Breast Cancer

Thomas Bachelot,Agathe Bajard,Isabelle Ray-Coquard,J. Provencal,David Coeffic,Cécile Agostini,Martial Boisseau,Régis Kaphan,Dominique Dramais,Corina Oprea,Rose-Marie Ferri-Dessens,Jean-Paul Guastalla,David Pérol

Final Results of ERASME-4: A Randomized Trial of First-Line Docetaxel plus either Capecitabine or Epirubicin for Metastatic Breast Cancer

2011

Thomas Bachelot
Agathe Bajard
Isabelle Ray-Coquard
J. Provencal
David Coeffic
Cécile Agostini
Martial Boisseau
Régis Kaphan
Dominique Dramais
Corina Oprea
Rose-Marie Ferri-Dessens
Jean-Paul Guastalla
David Pérol

Objective: To assess the efficacy of capecitabine plus docetaxel (XT) versus epirubicin plus docetaxel (ET) as first-line therapy for metastatic breast cancer (MBC). Patien

Keywords:

Capecitabine
Fluorouracil
Randomized controlled trial
Progression-free survival
Oncology
Epirubicin
Deoxycytidine
Medicine
Internal medicine
Metastatic breast cancer
Docetaxel
combination chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations